1. Home
  2. BMY
  3. BMY News

Latest Bristol-Myers Squibb Company (BMY) News on October 18, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
BMY

Benzinga

9 hours ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Bristol-Myers Squibb Company (BMY): A Bull Case Theory
BMY

Insider Monkey

12 hours ago

Bristol-Myers Squibb Company (BMY): A Bull Case Theory

BMY

MT Newswires

15 hours ago

Bernstein Initiates Coverage on Bristol-Myers Squibb With Market Perform Rating, $56 Price Target

Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
BMY

Zacks

15 hours ago

Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
BMY

Investor's Business Daily

a day ago

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.

BMY

Argus Research

2 days ago

Technical Assessment: Bullish in the Intermediate-Term

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
BMY

Investor's Business Daily

2 days ago

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment

Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘I Think It’s A Great Time To Consider Buying This One’
BMY

Insider Monkey

3 days ago

Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘I Think It’s A Great Time To Consider Buying This One’

The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Arthur J. Gallagher, TC Energy and Bridger Aerospace
BMY

Zacks

4 days ago

The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Arthur J. Gallagher, TC Energy and Bridger Aerospace

With 77% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns
BMY

Simply Wall St.

4 days ago

With 77% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns

Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
BMY

Zacks

6 days ago

Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know

Top Research Reports for Bristol-Myers, Arthur J. Gallagher & TC Energy
BMY

Zacks

6 days ago

Top Research Reports for Bristol-Myers, Arthur J. Gallagher & TC Energy

BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
BMY

Zacks

8 days ago

BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?

BMY

MT Newswires

9 days ago

UBS Adjusts Price Target on Bristol-Myers Squibb to $54 From $50, Maintains Neutral Rating

Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
BMY

Zacks

9 days ago

Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?

BMY

MT Newswires

11 days ago

TD Cowen Adjusts Price Target on Bristol-Myers Squibb to $59 From $53

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer’s Windfall
BMY

The Wall Street Journal

11 days ago

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer’s Windfall

Bristol-Myers Squibb Company (BMY): A Buzzing AI Health Stock to Add to Your Portfolio
BMY

Insider Monkey

13 days ago

Bristol-Myers Squibb Company (BMY): A Buzzing AI Health Stock to Add to Your Portfolio

These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
BMY

Simply Wall St.

13 days ago

These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well

BMY

MT Newswires

13 days ago

Correction: BMO Capital Maintains Price Target on Bristol-Myers Squibb to $53

BMY

MT Newswires

13 days ago

BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $70 From $53

Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
BMY

Benzinga

14 days ago

Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting

BMY

MT Newswires

14 days ago

Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $42, Maintains Underweight Rating

Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
BMY

BioPharma Dive

14 days ago

Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland

BMS receives FDA approval for Opdivo to treat NSCLC
BMY

Pharmaceutical Technology

14 days ago

BMS receives FDA approval for Opdivo to treat NSCLC

BMY

MT Newswires

14 days ago

Bristol-Myers Squibb Says FDA Approves Perioperative Treatment of Neoadjuvant Opdivo in NSCLC

Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
BMY

Zacks

14 days ago

Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
BMY

Business Wire

14 days ago

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
BMY

Investor's Business Daily

14 days ago

Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear

BMY

MT Newswires

14 days ago

Bristol-Myers Squibb's Opdivo Gets FDA Approval As Treatment for Resectable Non-Small Cell Lung Cancer

2 Passive Income Stocks to Load Up On in October
BMY

Motley Fool

15 days ago

2 Passive Income Stocks to Load Up On in October

STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
BMY

Zacks

16 days ago

STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls

PRME Stock Rises 11.8% on Collaboration With Bristol Myers
BMY

Zacks

16 days ago

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
BMY

Clinical Trials Arena

16 days ago

A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead

BMS and Prime ink potential $3.5bn deal to develop T cell therapies
BMY

Pharmaceutical Technology

17 days ago

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
BMY

Simply Wall St.

17 days ago

Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend

5 FDA decisions to watch in the fourth quarter
BMY

BioPharma Dive

17 days ago

5 FDA decisions to watch in the fourth quarter

Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
BMY

Insider Monkey

17 days ago

Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions

BMY

MT Newswires

17 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

BMY

MT Newswires

17 days ago

US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
BMY

Reuters

17 days ago

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug

Company News for Sep 30, 2024
BMY

Zacks

18 days ago

Company News for Sep 30, 2024

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
BMY

Benzinga

18 days ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

MT Newswires

18 days ago

Prime Medicine Enters Research Collaboration, License Agreement With Bristol Myers Squibb

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
BMY

GlobeNewswire

18 days ago

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Prime to narrow gene editing research as it strikes deal with Bristol Myers
BMY

BioPharma Dive

18 days ago

Prime to narrow gene editing research as it strikes deal with Bristol Myers

3 Surprisingly Underrated Stocks to Buy Right Now
BMY

Motley Fool

20 days ago

3 Surprisingly Underrated Stocks to Buy Right Now

These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
BMY

Barrons.com

20 days ago

These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More

Dow Rises to Record; Chinese Indexes Post Best Week in Years
BMY

The Wall Street Journal

20 days ago

Dow Rises to Record; Chinese Indexes Post Best Week in Years

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
BMY

Benzinga

20 days ago

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
BMY

Barrons.com

20 days ago

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More

BMY

MT Newswires

20 days ago

Bristol-Myers Squibb Potential Scalp Psoriasis Treatment Meets Targets

BMY

MT Newswires

20 days ago

Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns

BMY

Morningstar Research

20 days ago

Analyst Report: Bristol-Myers Squibb Company

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
BMY

Business Wire

20 days ago

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

FDA approves new Bristol Myers Squibb schizophrenia drug
BMY

Yahoo Finance Video

21 days ago

FDA approves new Bristol Myers Squibb schizophrenia drug

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
BMY

Business Wire

21 days ago

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
BMY

Investor's Business Daily

21 days ago

Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout

First Novel Schizophrenia Treatment in Decades Gains FDA Approval
BMY

The Wall Street Journal

21 days ago

First Novel Schizophrenia Treatment in Decades Gains FDA Approval

Bristol Myers schizophrenia drug, the first of its kind, approved by FDA
BMY

BioPharma Dive

21 days ago

Bristol Myers schizophrenia drug, the first of its kind, approved by FDA

BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial
BMY

Clinical Trials Arena

22 days ago

BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial

Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024
BMY

Insider Monkey

22 days ago

Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
BMY

Zacks

22 days ago

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
BMY

Benzinga

22 days ago

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients

BMY

MT Newswires

22 days ago

Jefferies Adjusts Bristol-Myers Squibb Price Target to $53 From $51, Maintains Hold Rating

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
BMY

Benzinga

22 days ago

Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability

BMY

Argus Research

23 days ago

Technical Assessment: Bullish in the Intermediate-Term

BMY

MT Newswires

23 days ago

2seventy bio, Bristol Myers Discontinue Phase 3 Abecma Study; Shares Fall Pre-Bell

BMY

MT Newswires

a month ago

Bristol-Myers Squibb Says Long-Term Data Support Zeposia's Efficacy in Relapsing Multiple Sclerosis

BMY

MT Newswires

a month ago

Purple Biotech Says Pancreatic Cancer Study Data Shows CM24 With Nivolumab and Chemo Improves Survival

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
BMY

Business Wire

a month ago

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
BMY

Zacks

a month ago

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
BMY

Pharmaceutical Technology

a month ago

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
BMY

Clinical Trials Arena

a month ago

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
BMY

Zacks

a month ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

BMY

MT Newswires

a month ago

Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen

BMY

MT Newswires

a month ago

Bristol-Myers Squibb Reports Opdivo, Yervoy Combination's Continued Survival Benefit in Advanced Melanoma

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
BMY

Motley Fool

a month ago

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
BMY

Business Wire

a month ago

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

Ten-year survival data show long-term benefit of immunotherapy in melanoma
BMY

BioPharma Dive

a month ago

Ten-year survival data show long-term benefit of immunotherapy in melanoma

Got $200? 2 Healthcare Stocks to Buy and Hold Forever
BMY

Motley Fool

a month ago

Got $200? 2 Healthcare Stocks to Buy and Hold Forever

ESMO 2024: BMS scores with ES-SCLC drug in patients with brain metastases
BMY

Clinical Trials Arena

a month ago

ESMO 2024: BMS scores with ES-SCLC drug in patients with brain metastases

With 77% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing
BMY

Simply Wall St.

a month ago

With 77% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
BMY

Business Wire

a month ago

Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
BMY

Zacks

a month ago

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
BMY

Zacks

a month ago

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

Prodrugs and patents: Enhancing therapy adherence and reducing side effects
BMY

Pharmaceutical Technology

a month ago

Prodrugs and patents: Enhancing therapy adherence and reducing side effects

Bristol Myers Squibb Announces Dividend
BMY

Business Wire

a month ago

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
BMY

Business Wire

a month ago

Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
BMY

Motley Fool

a month ago

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100

Implied Volatility Surging for Bristol-Myers (BMY) Stock Options
BMY

Zacks

a month ago

Implied Volatility Surging for Bristol-Myers (BMY) Stock Options

Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?
BMY

Zacks

a month ago

Argenx (ARGX) Moves 4.0% Higher: Will This Strength Last?

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
BMY

Business Wire

a month ago

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
BMY

Zacks

a month ago

Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know

Is Bristol-Myers Squibb Company (BMY) The Best Beaten Down Dividend Stocks to Invest in Now?
BMY

Insider Monkey

a month ago

Is Bristol-Myers Squibb Company (BMY) The Best Beaten Down Dividend Stocks to Invest in Now?

Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
BMY

Zacks

a month ago

Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?

US will still pay at least twice as much after negotiating drug prices
BMY

Reuters

a month ago

US will still pay at least twice as much after negotiating drug prices

2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
BMY

Motley Fool

2 months ago

2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High

Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?
BMY

Simply Wall St.

2 months ago

Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?

Bristol Myers Squibb’s CAMZYOS offers benefits in oHCM trial
BMY

Clinical Trials Arena

2 months ago

Bristol Myers Squibb’s CAMZYOS offers benefits in oHCM trial

Share on Social Networks: